Ada Rephaeli
Overview
Explore the profile of Ada Rephaeli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mansour O, Nudelman A, Rephaeli A, Phillips D, Cutts S, Evison B
Cancer Chemother Pharmacol
. 2022 Apr;
89(6):773-784.
PMID: 35460360
Purpose: Pixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin's lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone...
2.
Tarasenko N, Wilner H, Nudelman A, Kessler-Icekson G, Rephaeli A
Pharmaceuticals (Basel)
. 2021 Dec;
14(12).
PMID: 34959644
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors...
3.
Cheong A, McGrath S, Robinson T, Maliki R, Spurling A, Lock P, et al.
Biochem Pharmacol
. 2021 Jan;
185:114410.
PMID: 33428897
Cancer patients treated with doxorubicin are at risk of congestive heart failure due to doxorubicin-mediated cardiotoxicity via topoisomerase IIβ poisoning. Acute cardiac muscle damage occurs in response to the very...
4.
Nudelman V, Zahalka M, Nudelman A, Rephaeli A, Kessler-Icekson G
Eur J Pharmacol
. 2020 Jun;
882:173255.
PMID: 32553737
The anticancer prodrug butyroyloxymethyl diethylphosphate (AN-7), upon metabolic hydrolysis, releases the histone deacetylase inhibitor butyric acid and imparts histone hyperacetylation. We have shown previously that AN-7 increases doxorubicin-induced cancer cell...
5.
Oseghale A, Zhu X, Li B, Peterson K, Nudelman A, Rephaeli A, et al.
Blood Cells Mol Dis
. 2019 Jul;
79:102345.
PMID: 31351219
Pharmacologic induction of fetal hemoglobin (HbF) is an effective strategy for treating sickle cell disease (SCD) by ameliorating disease severity. Hydroxyurea is the only FDA-approved agent that induces HbF, but...
6.
Dahbash M, Sella R, Megiddo-Barnir E, Nisgav Y, Tarasenko N, Weinberger D, et al.
Int J Mol Sci
. 2019 Feb;
20(3).
PMID: 30736437
Choroidal neovascularization (CNV) is a complication of age-related macular degeneration and a major contributing factor to vision loss. In this paper, we show that in a mouse model of laser-induced...
7.
Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A
J Cell Biochem
. 2017 Nov;
119(4):3417-3428.
PMID: 29135083
The HDAC inhibitory activity of valproic acid (VPA) has led to on-going evaluation of it as an anticancer agent. The histone deacetylase (HDAC) inhibitor AN446, a prodrug of VPA, releases...
8.
Moyal L, Goldfeiz N, Gorovitz B, Rephaeli A, Tal E, Tarasenko N, et al.
Invest New Drugs
. 2017 Sep;
36(1):1-9.
PMID: 28884410
We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. AN-7 synergizes with doxorubicin (Dox), an anthracycline...
9.
Schaap-Fogler M, Bahar I, Rephaeli A, Dahbash M, Nudelman A, Livny E, et al.
J Ocul Pharmacol Ther
. 2017 Mar;
33(6):480-486.
PMID: 28338404
Purpose: To examine whether butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, inhibits chemically induced corneal neovascularization (NV) in mice. Methods: Corneal NV was induced in the right eye of male...
10.
Tarasenko N, Nudelman A, Rozic G, Cutts S, Rephaeli A
Invest New Drugs
. 2017 Mar;
35(4):412-426.
PMID: 28315153
The histone deacetylase (HDAC) inhibitory prodrugs of butyric (AN7) and valproic (AN446) acids, which release the active acids upon metabolic degradation, were studied examining their differential effects on the viability,...